Inhaled azacytidine plus chemo and durvalumab before lung cancer surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding an inhaled drug (azacytidine) to standard chemotherapy and durvalumab before surgery for early-stage lung cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage IB, II, or IIIA non-small cell lung cancer that can be removed by surgery.
- You must be willing to have a biopsy before treatment and have the tumor safely accessible for a biopsy.
- You have not had any prior treatment for this lung cancer.
- You are at least 18 years old and weigh more than 66 pounds (30 kg).
- You must be in good enough health to handle surgery, with adequate lung function.
- If you can become pregnant or father a child, you must agree to use effective birth control during and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
This trial tests adding durvalumab (an immunotherapy) after chemotherapy, surgery, and more durvalumab for people with early-stage, operable non-small cell lung cancer. It aims to see if this extra treatment helps prevent the cancer from coming back.
This phase 2 study tests durvalumab plus IPH5201 given before surgery to improve outcomes for people with resectable non-small cell lung cancer. It aims to shrink or control the cancer and make surgery more effective, using information about specific tumor markers like PD-L1.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests whether giving new drugs (amivantamab plus either lazertinib or chemotherapy) before surgery helps people with a specific type of lung cancer that can be removed. The goal is to shrink tumors and improve surgery outcomes.
This trial tests adding the immunotherapy drug Adebrelimab to chemotherapy before surgery for people with a type of lung cancer that has certain gene changes. The goal is to see if this combination helps shrink the tumor and improve outcomes.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.